Literature DB >> 23296392

Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.

Ronald F van Vollenhoven1.   

Abstract

Developments in our knowledge of the aetiology and pathogenesis of rheumatoid arthritis continued apace in 2012, and several important new advances were reported in the therapy of this disease. Culminating in the approval of a new therapy in the USA, the year offered new insights for clinicians and fresh hope for patients.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296392     DOI： 10.1038/nrrheum.2012.232

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

Authors:  Ronald F van Vollenhoven; Pierre Geborek; Kristina Forslind; Kristina Albertsson; Sofia Ernestam; Ingemar F Petersson; Katerina Chatzidionysiou; Johan Bratt
Journal:  Lancet       Date:  2012-03-29       Impact factor: 79.321

2.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Authors:  Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

4.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield
Journal:  Arthritis Rheum       Date:  2012-09

5.  Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.

Authors:  Ulrike Harre; Dan Georgess; Holger Bang; Aline Bozec; Roland Axmann; Elena Ossipova; Per-Johan Jakobsson; Wolfgang Baum; Falk Nimmerjahn; Eszter Szarka; Gabriella Sarmay; Grit Krumbholz; Elena Neumann; Rene Toes; Hans-Ulrich Scherer; Anca Irinel Catrina; Lars Klareskog; Pierre Jurdic; Georg Schett
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

6.  Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset.

Authors:  Sofia Ajeganova; Maria L Andersson; Ingiäld Hafström
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

7.  Effect of body mass index on mortality and clinical status in rheumatoid arthritis.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

8.  Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.

Authors:  P H de Jong; J M Hazes; P J Barendregt; M Huisman; D van Zeben; P A van der Lubbe; A H Gerards; M H de Jager; P B de Sonnaville; B A Grillet; J J Luime; A E Weel
Journal:  Ann Rheum Dis       Date:  2012-06-07       Impact factor: 19.103

9.  Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.

Authors:  Antonios Stavropoulos-Kalinoglou; Giorgos S Metsios; Vasileios F Panoulas; Peter Nightingale; Yiannis Koutedakis; George D Kitas
Journal:  Arthritis Res Ther       Date:  2012-07-05       Impact factor: 5.156

10.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis.

Authors:  Soumya Raychaudhuri; Cynthia Sandor; Eli A Stahl; Jan Freudenberg; Hye-Soon Lee; Xiaoming Jia; Lars Alfredsson; Leonid Padyukov; Lars Klareskog; Jane Worthington; Katherine A Siminovitch; Sang-Cheol Bae; Robert M Plenge; Peter K Gregersen; Paul I W de Bakker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330
  10 in total
  9 in total

1.  Regulation of the Cell Cycle and Inflammatory Arthritis by the Transcription Cofactor LBH Gene.

Authors:  Shinji Matsuda; Deepa Hammaker; Katharyn Topolewski; Karoline J Briegel; David L Boyle; Steven Dowdy; Wei Wang; Gary S Firestein
Journal:  J Immunol       Date:  2017-08-14       Impact factor: 5.422

2.  Propofol inhibits cell proliferation and invasion in rheumatoid arthritis fibroblast-like synoviocytes via the nuclear factor-κB pathway.

Authors:  Song Wang; Shuhong Liang; Xiaoyu Zhao; Yujie He; Yuedong Qi
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

3.  The Rheumatoid Arthritis Risk Gene LBH Regulates Growth in Fibroblast-like Synoviocytes.

Authors:  Anna-Karin H Ekwall; John W Whitaker; Deepa Hammaker; William D Bugbee; Wei Wang; Gary S Firestein
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

4.  Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.

Authors:  Sanchita Raychaudhuri; Christine Abria; Zachary T Harmany; Charles M Smith; Smriti Kundu-Raychaudhuri; Siba P Raychaudhuri; Abhijit J Chaudhari
Journal:  Int J Rheum Dis       Date:  2019-10-29       Impact factor: 2.454

5.  Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.

Authors:  Kalyan Chakravarthy; Robert Faltus; Gain Robinson; Raquel Sevilla; John Shin; Mark Zielstorff; Alan Byford; Erica Leccese; Michael J Caniga; SuChun Hseih; Shuli Zhang; Chi-Sung Chiu; Jie Zhang-Hoover; Lily Y Moy; Robbie L McLeod; Dana Stoffregen; Weisheng Zhang; Anwar Murtaza; Milenko Cicmil
Journal:  BMC Musculoskelet Disord       Date:  2014-12-04       Impact factor: 2.362

6.  Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis.

Authors:  Inês Pedro Perpétuo; Joana Caetano-Lopes; Ana Maria Rodrigues; Raquel Campanilho-Marques; Cristina Ponte; Helena Canhão; Mari Ainola; João Eurico Fonseca
Journal:  RMD Open       Date:  2017-07-13

7.  Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.

Authors:  Qiao Yang; Yumo Zhao; Chen Li; Yaping Luo; Weixin Hao; Wen Zhang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 8.  Insights in the Role of Lipids, Oxidative Stress and Inflammation in Rheumatoid Arthritis Unveiled by New Trends in Lipidomic Investigations.

Authors:  Helena Beatriz Ferreira; Tânia Melo; Artur Paiva; Maria do Rosário Domingues
Journal:  Antioxidants (Basel)       Date:  2021-01-02

Review 9.  What is the future of targeted therapy in rheumatology: biologics or small molecules?

Authors:  Attila Mócsai; László Kovács; Péter Gergely
Journal:  BMC Med       Date:  2014-03-13       Impact factor: 8.775
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.